User:Magnovvig/sandbox

In November 2020, Segreto and Deigin wrote that the "genetic structure of SARS-CoV-2 does not rule out a laboratory origin" and found that the "SARS-COV-2 chimeric structure and furin cleavage site might be the result of genetic manipulation."

Qiu.

EU-China CAI
The EU-China Comprehensive Agreement on Investment (CAI) is a bilateral treaty between the European Union and the People's Republic of China concerning investment between the parties, but not trade. It has been under negotiation since 2014. The negotiations on the text have concluded on 2020-12-30 following personal involvement of Xi Jinping.

History
In May 2021, the von der Leyen Commission suspended efforts to ratify the CAI because "China [had] imposed sanctions on several high-profile members of the European Parliament, three members of national parliaments, two EU committees, and several China-focused European academics" in response to their questions on the Xinjiang genocide and the application of sanctions on four officials from that province. Trade commissioner Valdis Dombrovskis said: "the environment is not conducive to the ratification of the agreement."

GeneOne
GeneOne Life Science (GLS) is a KOSPI-listed company headquartered in Seoul, South Korea. The company, whose entry into biotechnology began in 2005, "is focused on gene-based therapies and vaccines". The company changed names twice, from Dong-Il Fabric to VGXI International to its current label in 2014. Its "global clinical development group is based in Blue Bell, Pennsylvania. VGXI Inc. is a wholly owned subsidiary and is based in Woodlands, Texas. VGXI is known as the largest Contract Manufacturing Organization able to supply cGMP-grade DNA plasmids for clinical use.

History
Before August 2016, GLS began tests of a DNA vaccine against Zika in Miami, due to the outbreak there which had infected at least 14 people. The injection technique of electroporation is employed by GLS, in which "genes from the virus are shot under high pressure into a person’s arm."

In April 2020, GLS and Inovio shared positive results for their MERS DNA vaccine.

In May 2020, GLS announced FDA approval of a Phase 2 Study of their GLS-1200 nasal spray product for COVID-19 prevention. Their product seeks to train cells to produce nitric oxide which "has been shown to inhibit SARS coronavirus growth and infectivity... The study will investigate whether three-times daily nasal administration of GLS-1200 over 4 weeks can prevent infection with COVID-19 while in use."